MTOR and type 2 diabetes mellitus: It has been previously demonstrated that Metformin, a relatively non-toxic biguanide widely used by millions of type II diabetics around the world, possesses antileukemic activity via, in part, AMPK-mediated antagonism of mTOR/Akt signaling [30].